FTC review periods end for AbbVie-ImmunoGen $10.1B deal and $4B BMS-RayzeBio buyout

Ab­b­Vie moved ahead with its $10.1 bil­lion ac­qui­si­tion of an­ti­body-drug con­ju­gate biotech Im­muno­Gen, while Bris­tol My­ers Squibb’s big ac­qui­si­tion of ra­dio­phar­ma­ceu­ti­cals biotech Rayze­Bio is like­ly on the way too, de­spite the Fed­er­al Trade Com­mis­sion’s height­ened at­ten­tion on phar­ma M&A.

Ab­b­Vie an­nounced the clo­sure of its buy on Mon­day, sev­er­al days af­ter the end of the wait­ing pe­ri­od for the FTC. The 30-day wait­ing pe­ri­od un­der the Hart-Scott-Rodi­no An­titrust Im­prove­ments Act (HSR Act) al­lowed the FTC to ob­ject to the Ab­b­Vie-Im­muno­Gen propo­si­tion un­til Feb. 7.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.